“The launch of Dr Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is an important addition to our Pain/Analgesics portfolio of OTC products, and represents our continued commitment to the Private Label OTC space,” said Marc Kikuchi, CEO, North America Generics, Dr Reddy’s Laboratories.
“We are pleased to partner with Encube Ethicals to bring this product to market for the benefit of consumers,” he added.
Dr Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), is used for the temporary relief of arthritis pain only in hand, wrist, elbow (upper body areas) and foot, ankle, knee (lower body areas).
Voltaren Arthritis Pain brand had total U.S. retail sales of approximately $44 million since launch in May 2020 according to IRI.
Dr. Reddy’s Diclofenac Sodium Topical Gel, 1% (OTC), will soon be available in multiple pack sizes to allow consumers a variety of purchasing options. Voltaren is a trademark of Novartis Corporation.
Dr Reddys Laboratories Ltd is currently trading at Rs4,378.60, up by Rs30.6 or 0.7% from its previous closing of Rs4,348 on the BSE.